What do you think will be the demand for a medical device that can cost upwards of $100,000 and so far is eligible for reimbursements in only two European countries?  Negligible perhaps?

Well, that was the conclusion of big institutional investors who apparently turned up their noses at the initial public offering this month of Al Mann’s latest company to go public, Second Sight Medical Products.

It’s sort of hard to blame them, just take a look at the device, which is pictured on page 30 of this edition of the Business Journal...

Join our Membership to get the full story.


Are you a current Member? Sign In